Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment. If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply ...
Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have divulged cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and ...
Cyclin-dependent kinase inhibitor protein (also known as CKIs, CDIs, or CDKIs) is a protein which inhibits the enzyme cycling-dependent kinase (CDK) and Cyclin activity by stopping the cell cycle if ...
Scientists at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have described tricyclic compounds acting ...
Enzymes that drive cancer growth are already addressed by several drugs, but there’s still room to improve and expand this approach. BeiGene sees opportunity in the lead program of Ensem Therapeutics ...
Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients ...
Please provide your email address to receive an email when new articles are posted on . The addition of palbociclib to anti-HER2 and endocrine therapy extended PFS by more than a year. The regimen ...
– Filing acceptance based on Phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, ...
The Purvalanol A (CDK Inhibitor) market has demonstrated impressive growth, expanding from $0.64 billion in 2025 to $0.7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results